Drug discoveries towards Kv1.5 potassium channel

Current Topics in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 339-347

  Yang, Qian ^a   Wang, Xiaojian ^a   Du, Lupei ^a,c   Li, Minyong ^b,c   You, Qidong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b GEORGIA STATE UNIVERSITY   (United States)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Atrial diseases; Cardiac; Cardiotoxicities; Chemotherapeutic; IKur potassium channel; Kv1.5; Tumor; Ultra rapid delayed rectifier

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; 2 HYDROXYETHYLAMIDE DERIVATIVE; 2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 4 AMINOPYRIDINE; ANTHRANILIC ACID DERIVATIVE; AVE 1231; DIISOPROPYLAMIDE DERIVATIVE; DISOPYRAMIDE; DOXORUBICIN; DRONEDARONE; FLUOROURACIL; HETEROCYCLIC COMPOUND; ICA 32; ISOQUINOLINE DERIVATIVE; NIP 142; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5; POTASSIUM CHANNEL KV1.5 BLOCKING AGENT; PROPAFENONE; QUINOLINE; S 0100176; S 20951; S 9947; TEDISAMIL; TETRYLAMMONIUM; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT;

ANTIARRHYTHMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; CANCER GROWTH; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BINDING SITE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG TARGETING; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; LIGAND BINDING; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; STOMACH CANCER; STRUCTURE ACTIVITY RELATION;

EID: 66449101854     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609788317810     Document Type: Review

References (86)

1. Warmke, J.W.; Ganetzky, B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl. Acad. Sci. USA 1994, 91, 3438-3442.
2. Yellen, G. The moving parts of voltage-gated ion channels. Q Rev. Biophys. 1998, 31, 239-295.
3. MacKinnon, R. Potassium channels and the atomic basis of selective ion conduction (Nobel Lecture). Angew. Chem. Int. Ed. Engl. 2004, 43, 4265-4277.
4. Jiang, Y.; Lee, A.; Chen, J.; Cadene, M.; Chait, B.T.; MacKinnon, R The open pore conformation of potassium channels. Nature 2002, 417, 523-526.
5. Roux, B.; MacKinnon, R. The cavity and pore helices in the KcsA K+ channel: Electrostatic stabilization of monovalent cations. Science 1999, 285, 100-102.
6. Jiang, Y.; Lee, A.; Chen, J.; Ruta, V.; Cadene, M.; Chait, B.T.; MacKinnon, R. X-ray structure of a voltage-dependent K+ channel. Nature 2003, 423, 33-41.
7. Long, S.B.; Campbell, E.B.; Mackinnon, R. Voltage sensor of Kv1.2: structural basis of electromechanical coupling. Science 2005, 309, 903-908.
8. Long, S.B.; Campbell, E.B.; Mackinnon, R. Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 2005, 309, 897-903.
9. Hackos, D.H.; Chang, T.H.; Swartz, K.J. Scanning the intracellular S6 activation gate in the shaker K+ channel. J. Gen. Physiol. 2002, 119, 521-532.
10. Lu, Z.; Klem, A.M.; Ramu, Y. Coupling between voltage sensors and activation gate in voltage-gated K+ channels. J. Gen. Physiol. 2002, 120, 663-676.
11. Wang, Z.; Fermini, B.; Nattel, S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ. Res. 1993, 73, 1061-1076.
12. Van Wagoner, D.R.; Pond, A.L.; McCarthy, P.M. Trimmer JS, Nerbonne JM: Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ. Res. 1997, 80, 772-781.
13. Lip, G.Y.; Tse, H.F. Management of atrial fibrillation. Lancet 2007, 370, 604-618.
14. Kaye, D.M.; Krum, H. Drug discovery for heart failure: A new era or the end of the pipeline? Nat. Rev. Drug Discov. 2007, 6, 127-139.
15. Conway, E.; Musco, S.; Kowey, P.R. New horizons in antiarrhythmic therapy: Will novel agents overcome current deficits? Am. J. Cardiol. 2008, 102, 12H-19H.
16. O'Grady, S.M.; Lee, S.Y. Molecular diversity and function of voltage-gated (Kv) potassium channels in epithelial cells. Int. J. Biochem. Cell Biol. 2005, 37, 1578-1594.
17. Steele, D.F.; Eldstrom, J.; Fedida, D. Mechanisms of cardiac potassium channel trafficking. J. Physiol. 2007, 582, 17-26
18. Hirota, Y.; Kurata, Y.; Kato, M.; Notsu, T.; Koshida, S.; Inoue, T.; Kawata, Y.; Miake, J.; Bahrudin, U.; Li, P.; Hoshikawa, Y.; Yamamoto, Y.; Igawa, O.; Shirayoshi, Y.; Nakai, A.; Ninomiya, H.; Higaki, K.; Hiraoka, M.; Hisatome, I. Functional stabilization of Kv1.5 protein by Hsp70 in mammalian cell lines. Biochem. Biophys. Res. Commun. 2008, 372, 469-474.
19. Koutsouki, E.; Lam, R.S.; Seebohm, G.; Ureche, O.N.; Ureche, L.; Baltaev, R.; Lang, F. Modulation of human Kv1.5 channel kinetics by N-cadherin. Biochem. Biophys. Res. Commun. 2007, 363, 18-23.
20. Feng, J.; Wible, B.; Li, G.R.; Wang, Z.; Nattel, S. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ. Res. 1997, 80, 572-579.
21. Brandt, M.C.; Priebe, L.; Bohle, T.; Sudkamp, M.; Beuckelmann, D.J. The ultrarapid and the transient outward K(+) current in human atrial fibrillation. Their possible role in postoperative atrial fibrillation. J. Mol. Cell Cardiol. 2000, 32, 1885-1896.
22. Brunner, M.; Kodirov, S.A.; Mitchell, G.F; Buckett, P.D.; Shibata, K.; Folco, E.J.; Baker, L.; Salama, G.; Chan, D.P.; Zhou, J.; Koren, G. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. Am.J. Physiol. Heart Circ. Physiol. 2003, 285, H194-203.
23. Bonnet, S.; Archer, S.L.; Allalunis-Turner, J.; Haromy, A.; Beaulieu, C.; Thompson, R.; Lee, C.T.; Lopaschuk, G..D.; Puttagunta, L.; Bonnet, S.; Harry, G.; Hashimoto, K.; Porter, C.J.; Andrade, M.A; Thebaud, B.; Michelakis, E.D. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11, 37-51.
24. Ousingsawat, J.; Spitzner, M.; Puntheeranurak, S.; Terracciano, L.; Tornillo, L.; Bubendorf, L.; Kunzelmann, K.; Schreiber, R. Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin. Cancer Res. 2007, 13, 824-831.
25. Han, Y.; Shi,Y.; Han, Z.; Sun, L.; Fan, D. Detection of potassium currents and regulation of multidrug resistance by potassium channels in human gastric cancer cells. Cell Biol. Int. 2007, 31, 741-747.
26. Lan, M.; Shi, Y.; Han, Z.; Hao, Z.; Pan, Y.; Liu, N.; Guo, C.; Hong, L.; Wang, J.; Qiao, T.; Fan, D. Expression of delayed rectifier potassium channels and their possible roles in proliferation of human gastric cancer cells. Cancer Biol. Ther. 2005, 4, 1342-1347.
27. Franqueza, L.; Longobardo, M.; Vicente, J.; Delpon, E.; Tamkun, M.M.; Tamargo, J.; Snyders, D.J.; Valenzuela, C. Molecular determinants of stereoselective bupivacaine block of hKv1.5 channels. Circ. Res. 1997, 81, 1053-1064.
28. Caballero, R.; Moreno, I.; Gonzalez, T.; Valenzuela, C.; Tamargo, J.; Delpon, E. Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). Cardiovasc. Res. 2002, 56, 104-117.
29. Arechiga, I.A.; Barrio-Echavarria, G..F.; Rodriguez-Menchaca, A.A.; Moreno-Galindo, E.G.; Decher, N.; Tristani-Firouzi, M.; Sanchez-Chapula, J.A.; Navarro-Polanco, R.A. Kv1.5 open channel block by the antiarrhythmic drug disopyramide: Molecular determinants of block. J. Pharmacol. Sci., 2008, 108, 49-55.
30. Decher, N.; Pirard, B.; Bundis, F.; Peukert, S.; Baringhaus, K.H.; Busch, A.E.; Steinmeyer, K.; Sanguinetti, M.C. Molecular basis for Kv1.5 channel block: Conservation of drug binding sites among voltage-gated K+ channels. J. Biol. Chem. 2004, 279, 394-400.
31. Decher, N.; Kumar, P.; Gonzalez, T.; Pirard, B.; Sanguinetti, M.C. Binding site of a novel Kv1.5 blocker: A "foot in the door" against atrial fibrillation. Mol. Pharmacol. 2006, 70, 1204-1211.
32. Rodriguez-Menchaca, A.; Ferrer-Villada, T.; Lara, J.; Fernandez, D.; Navarro-Polanco, R.A.; Sanchez-Chapula, J.A. Block of HERG channels by berberine: Mechanisms of voltage- and statedependence probed with site-directed mutant channels. J. Cardiovasc. Pharmacol. 2006, 47, 21-29.
33. Wattanasirichaigoon, D.; Beggs, A.H. Molecular genetics of longQT syndrome. Curr. Opin. Pediatr. 1998, 10, 628-634
34. Pirard, B.; Brendel, J.; Peukert, S. The discovery of Kv1.5 blockers as a case study for the application of virtual screening approaches. J. Chem. Inf. Model. 2005, 45, 477-485.
35. Liu, H.L.; Chen, C.W.; Lin, J.C. Homology models of the tetramerization domain of six eukaryotic voltage-gated potassium channels Kv1.1-Kv1.6. J. Biomol. Struct. Dyn. 2005, 22, 387-398.
36. Ander, M.; Luzhkov, V.B.; Aqvist, J. Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state - docking and computer simulations of a homology model. Biophys. J. 2008, 94, 820-831.
37. Yang, Q.; Du, L.; Wang, X.; Li, M.; You, Q. Modeling the binding modes of Kv1.5 potassium channel and blockers. J. Mol. Graph. Model. 2008, 27, 178-187.
38. Rezazadeh, S.; Claydon, T.W.; Fedida, D. KN-93 (2-[N-(2hydroxyethyl)]- N-(4-methoxybenzenesulfonyl)]amino-N-(4chlorocinn amyl)- N-methylbenzylamine), a calcium/calmodulindependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J. Pharmacol. Exp. Ther. 2006, 317, 292-299.
39. Page, R.L.; Roden, D.M. Drug therapy for atrial fibrillation: Where do we go from here? Nat. Rev. Drug Discov. 2005, 4, 899-910.
40. Lombardi, F.; Borggrefe, M.; Ruzyllo, W.; Luderitz, B. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: The ACOMET- II (Azimilide-CardiOversion MaintEnance Trial-II) trial. Eur. Heart J. 2006, 27, 2224-2231.
41. Naccarelli, G.V.; Wolbrette, D.L.; Khan, M.; Bhatta, L.; Hynes, J.; Samii, S.; Luck, J. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: Comparative efficacy and results of trials. Am. J. Cardiol. 2003, 91, 15D-26D.
42. Elming, H.; Brendorp, B.; Pehrson, S.; Pedersen, O.D.; Kober, L.; Torp-Petersen, C. A benefit-risk assessment of class III antiarrhythmic agents. Expert Opin. Drug Saf. 2004, 3, 559-577
43. Peukert, S.; Brendel, J.; Pirard, B.; Bruggemann, A.; Below, P.; Kleemann, H.W.; Hemmerle, H.; Schmidt, W. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5. J. Med. Chem. 2003, 46, 486-498.
44. Bachmann, A.; Gutcher, I.; Kopp, K.; Brendel, J.; Bosch, R.F.; Busch, A.E.; Gogelein, H. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes. Naunyn. Schmiedebergs Arch. Pharmacol. 2001, 364, 472-478.
45. Nattel, S.; Zeng, F.D. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. J. Pharmacol. Exp. Ther. 1984, 229. 83-291.
46. de Haan, S.; Greiser, M.; Harks, E.; Blaauw, Y.; van Hunnik, A.; Verheule, S.; Allessie, M.; Schotten, U. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation 2006, 114, 1234-1242.
47. Gogelein, H.; Brendel, J.; Steinmeyer, K.; Strubing, C.; Picard, N.; Rampe, D.; Kopp, K.; Busch, A.E.; Bleich, M. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370, 183-192.
48. Oros, A.; Volders, P.G.; Beekman, J.D.; van der Nagel, T.; Vos, M.A. Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block. Heart Rhythm. 2006, 3, 1339-1345.
49. Wirth, K.J.; Paehler, T.; Rosenstein, B.; Knobloch, K.; Maier, T.; Frenzel, J.; Brendel, J.; Busch, A.E.; Bleich, M. Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc. Res. 2003, 60, 298-306.
50. Blaauw, Y.; Gogelein, H.; Tieleman, R.G.; van Hunnik, A.; Schotten, U.; Allessie, M.A. "Early" class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004, 110, 717-1724.
51. Ehrlich, J.R.; Ocholla, H.; Ziemek, D.; Rutten, H.; Hohnloser, S.H.; Gogelein, H. Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231. J. Cardiovasc. Pharmacol. 2008, 51, 380-387.
52. Wirth, K.J.; Brendel, J.; Steinmeyer, K.; Linz, D.K.; Rutten, H.; Gogelein, H. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J. Cardiovasc. Pharmacol. 2007, 49, 197-206.
53. Linz, D.K.; Afkham, F.; Itter, G..; Rutten, H.; Wirth, K.J. Effect of atrial electrical remodeling on the efficacy of antiarrhythmic drugs: comparison of amiodarone with I(Kr)- and I(to)/IKur-blockade in vivo. J. Cardiovasc. Electrophysiol. 2007, 18, 1313-1320.
54. Peukert, S.; Brendel, J.; Pirard, B.; Strubing, C.; Kleemann, H.W.; Bohme, T.; Hemmerle, H. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg. Med. Chem. Lett. 2004, 14, 2823-2827.
55. Lloyd, D.G.; Buenemann, C.L.; Todorov, N.P.; Manallack, D.T.; Dean, P.M. Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. J. Med. Chem. 2004, 47, 493-496.
56. Trotter, B.W.; Nanda, K.K.; Kett, N.R.; Regan, C.P.; Lynch, J.J.; Stump, G.L.; Kiss, L.; Wang, J.; Spencer, R.H.; Kane, S.A.; White, R.B.; Zhang, R.; Anderson, K.D.; Liverton, N.J.; McIntyre, C.J.; Beshore, D.C.; Hartman, G.D.; Dinsmore, C.J. Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. J. Med. Chem. 2006, 49, 6954-6957.
57. Regan, C.P.; Kiss, L.; Stump, G.L.; McIntyre, C.J.; Beshore, D.C.; Liverton, N.J.; Dinsmore, C.J.; Lynch, J.J.Jr., Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino) methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure. J. Pharmacol. Exp. Ther. 2008, 324, 322-330.
58. Fedida, D.; Eldstrom, J.; Hesketh, J.C.; Lamorgese, M.; Castel, L.; Steele, D.F.; Van Wagoner, D.R. Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes. Circ. Res. 2003, 93, 744-751.
59. Nanda, K.K.; Nolt, M.B.; Cato, M. J.; Kane, S.A.; Kiss, L.; Spencer, R.H.; Wang, J.; Lynch, J.J.; Regan, C.P.; Stump, G.L.; Li, B.; White, R.; Yeh, S.; Bogusky, M.J.; Bilodeau, M.T.; Dinsmore, C.J.; Lindsley, C.W.; Hartman, G.D.; Wolkenberg, S.E.; Trotter, B.W. Potent antagonists of the Kv1.5 potassium channel: Synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3yl) acetamides. Bioorg. Med. Chem. Lett. 2006, 16, 5897-5901.
60. Jackson, C.M.; Blass, B.; Coburn, K.; Djandjighian, L.; Fadayel, G.; Fluxe, A.J.; Hodson, S.J.; Janusz, J.M.; Murawsky, M.; Ridgeway, J.M.; White, R.E; Wu, S. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. Bioorg. Med. Chem. Lett. 2007, 17, 282-284.
61. Blass, B.E.; Coburn, K.; Lee, W.; Fairweather, N.; Fluxe, A.; Wu, S.; Janusz, J.M.; Murawsky, M.; Fadayel, G.M.; Fang, B.; Hare, M.; Ridgeway, J.; White, R.; Jackson, C.; Djandjighian, L.; Hedges, R.; Wireko, F.C.; Ritter, A.L. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation. Bioorg. Med. Chem. Lett. 2006, 16, 4629-4632.
62. Wu, S.; Fluxe, A.; Sheffer, J.; Janusz, J.M.; Blass, B.E.; White, R.; Jackson, C.; Hedges, R.; Murawsky, M.; Fang, B.; Fadayel, G.M.; Hare, M.; Djandjighian, L. Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers. Bioorg. Med. Chem. Lett. 2006, 16, 6213-6218.
63. Wu, S.; Fluxe, A.; Janusz, J.M.; Sheffer, J.B.; Browning, G.; Blass, B.; Cobum, K.; Hedges, R.; Murawsky, M.; Fang, B.; Fadayel, G.M.; Hare, M.; Djandjighian, L. Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers. Bioorg. Med. Chem. Lett. 2006, 16, 5859-5863.
64. Fluxe, A.; Wu, S.; Sheffer, J.B.; Janusz, J.M.; Murawsky, M.; Fadayel, G.M.; Fang, B.; Hare, M.; Djandjighian, L. Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers. Bioorg. Med. Chem. Lett. 2006, 16,5855-5858.
65. Gross, M.F.; Beaudoin, S.; McNaughton-Smith, G.; Amato, G.S.; Castle, N.A. Huang C, Zou A, Yu W: Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel. Bioorg. Med. Chem. Lett. 2007, 17, 2849-2853.
66. Lloyd, J.; Atwal, K.S.; Finlay, H.J.; Nyman, M.; Huynh, T.; Bhandaru, R.; Kover, A.; Schmidt, J.; Vaccaro, W.; Conder, M.L.; Jenkins-West, T.; Levesque, P. Benzopyran sulfonamides as KV1.5 potassium channel blockers. Bioorg. Med. Chem. Lett. 2007, 17, 3271-3275.
67. Finlay, H.J.; Lloyd, J.; Nyman, M.; Conder, M.L.; West, T.; Levesque, P.; Atwal, K. Pyrano-[2,3b]-pyridines as potassium channel antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 2714-2718.
68. Matsuda, T.; Masumiya, H.; Tanaka, N.; Yamashita, T.; Tsuruzoe, N.; Tanaka, Y.; Tanaka, H.; Shigenoba, K. Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current. Life Sci. 2001, 68, 2017-2024.
69. Matsuda, T.; Ito, M.; Ishimaru, S.; Tsuruoka, N.; Saito, T.; Iida-Tanaka, N.; Hashimoto, N.; Yamashita, T.; Tsuruzoe, N.; Tanaka, H.; Shigenobu, K. Blockade by NIP-142, an antiarrhythmic agent, of carbachol-induced atrial action potential shortening and GIRK1/4 channel. J. Pharmacol. Sci. 2006, 101,303-310.
70. Nagasawa, H.; Fujiki, A.; Fujikura, N.; Matsuda, T.; Yamashita, T.; Inoue, H. Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter. Circ. J. 2002, 66,185-191.
71. Matsuda, T.; Takeda, K.; Ito, M.; Yamagishi, R.; Tamura, M.; Nakamura, H.; Tsuruoka, N.; Saito, T.; Masumiya, H.; Suzuki, T.; Iida-Tanaka, N.; Itokawa-Matsuda, M.; Yamashita, T.; Tsuruzoe, N.; Tanaka, H.; Shigenobu, K. Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium. J. Pharmacol. Sci. 2005, 98, 33-40
72. Ford, J.W.; Milnes, J.T. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): Rationale, pharmacology and evidence for potential therapeutic value. J. Cardiovasc. Pharmacol. 2008, 52, 105-120.
73. Yang, Q.; Du, L.; Tsai, K-C.; Wang, X.; Li, M.; You, Q. Pharmacophore Mapping for Kv1.5 Potassium Channel Blockers. QSAR Comb. Sci. 2009, 28, 59-71.
74. Khanderia, U.; Wagner, D.; Walker, P.C.; Woodcock, B.; Prager, R. Amiodarone for atrial fibrillation following cardiac surgery: Development of clinical practice guidelines at a university hospital. Clin Cardiol. 2007.
75. Touboul, P.; Brugada, J.; Capucci, A.; Crijns, H.J.; Edvardsson, N.; Hohnloser, S.H. Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur. Heart J. 2003, 24,1481-1487.
76. Hohnloser, S.H.; Dorian, P.; Straub, M.; Beckmann, K.; Kowey, P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J. Am. Coll. Cardiol. 2004, 44, 99-104.
77. Orth, P.M.; Hesketh, J.C.; Mak, C.K.; Yang, Y.; Lin, S.; Beatch, G.N.; Ezrin, A.M.; Fedida, D. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc. Res. 2006, 70, 486-496.
78. Fedida, D.; Orth, P.M.; Chen, J.Y.; Lin, S.; Plouvier, B.; Jung, G.; Ezrin, A.M.; Beatch, G.N. The mechanism of atrial antiarrhythmic action of RSD1235. J. Cardiovasc. Electrophysiol. 2005, 16,1227-1238.
79. Vernakalant. RSD 1235, RSD-1235, RSD1235. Drugs R. D. 2007, 8, 259-265.
80. Billman, G.E. RSD-1235. Cardiome. Curr. Opin. Investig. Drugs 2003, 4,352-354.
81. Fedida, D. Vernakalant (RSD1235): A novel, atrial-selective antifibrillatory agent. Expert Opin. Investig Drugs 2007, 16, 519-532.
82. Roy, D.; Rowe, B.H.; Stiell, I.G.; Coutu, B.; Ip, J.H.; Phaneuf, D.; Lee, J.; Vidaillet, H.; Dickinson, G.; Grant, S.; Ezrin, A.M.; Beatch, G.N. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol. 2004, 44, 2355-2361.
83. Goldstein, R.N.; Khrestian, C.; Carlsson, L.; Waldo, A.L. Azd7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J. Cardiovasc. Electrophysiol. 2004, 15,1444-1450.
84. Persson, F.; Carlsson, L.; Duker, G.; Jacobson, I. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J. Cardiovasc. Electrophysiol. 2005, 16, 329-341.
85. Lofberg, L.; Jacobson, I.; Carlsson, L. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: A comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace. 2006, 8, 549-557.
86. Crijns, H.J.; Van Gelder, I.C.; Walfridsson, H.; Kulakowski, P.; Ronaszeki, A.; Dedek, V.; Malm, A.; Almgren, O. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm. 2006, 3, 1321-1331.